Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Nivolumab [USAN:INN]
RN: 946414-94-4
UNII: 31YO63LBSN

Notes

  • A genetically engineered, fully human immunoglobulin G4 (IgG4) monoclonal anti programmed death-1/PD-1 protein antibody.

    NCI: A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation. (NCI Thesaurus)
  • A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.

Molecular Formulas

  • C6362-H9862-N1712-O1995-S42
  • Unspecified
 

Classification Codes

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Antiviral (COVID-19)
  • Immune Checkpoint Inhibitors

Names and Synonyms

Results Name

  • Nivolumab [USAN:INN]

Name of Substance

  • MDX-1106
  • Nivolumab
  • Nivolumab [USAN:INN]

MeSH Heading

  • Nivolumab

Synonyms

  • Anti-PD-1 human monoclonal antibody MDX-1106.
  • BMS 936558
  • BMS-936558
  • HSDB 8256
  • MDX 1106
  • MDX-1106
  • Nivolumab
  • ONO 4538
  • ONO-4538
  • Opdivo
  • UNII-31YO63LBSN

Registry Numbers

CAS Registry Number

  • 946414-94-4

FDA UNII

  • 31YO63LBSN

System Generated Number

  • 0946414944